Value of increase in bladder capacity in treatment of refractory monosymptomatic nocturnal enuresis in children

Urology. 2002 Dec;60(6):1090-4. doi: 10.1016/s0090-4295(02)02127-1.

Abstract

Objectives: To evaluate children with refractory monosymptomatic nocturnal enuresis to determine whether detrusor overactivity (DOA) plays a role in 4 weeks of unsuccessful treatment with retention control training (RCT); whether an increase in bladder capacity can eventually be obtained by RCT plus oxybutynin; and whether the increase in capacity is the primary key to success.

Methods: Sixty-eight children with refractory monosymptomatic nocturnal enuresis were included. They all had a maximal cystometric capacity less than the age-expected value. RCT was done by water loading and retention to the point of urgency once daily. During training, changes in bladder capacity were evaluated by voiding charts. If after 4 weeks of RCT, less than a 10% increase in bladder capacity was noted, oral oxybutynin was added.

Results: The incidence of DOA was 66%. After 4 weeks of RCT, the bladder capacity increased in 20.6%. Combining RCT with oxybutynin led in the end to normalization of the bladder capacity in 79.4%. Older age and high-pressure DOA negatively influenced the ability to increase the bladder capacity. Fifteen children became completely dry, mainly by converting enuresis to nocturia.

Conclusions: Unsuccessful RCT is often caused by DOA, especially if a bladder capacity rise of at least 10% cannot be achieved within 4 weeks. If oxybutynin is added to the treatment, normalization of bladder capacity can be obtained in most. This increased bladder capacity cures enuresis only in a minority by sharpening their arousal and provoking nocturia.

MeSH terms

  • Administration, Oral
  • Child
  • Combined Modality Therapy
  • Enuresis / physiopathology*
  • Enuresis / rehabilitation
  • Enuresis / therapy*
  • Female
  • Humans
  • Male
  • Mandelic Acids / administration & dosage*
  • Parasympatholytics / administration & dosage*
  • Treatment Outcome
  • Urinary Bladder / drug effects
  • Urinary Bladder / physiopathology*
  • Urine

Substances

  • Mandelic Acids
  • Parasympatholytics
  • oxybutynin